<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00501631</url>
  </required_header>
  <id_info>
    <org_study_id>ALK21-014</org_study_id>
    <nct_id>NCT00501631</nct_id>
  </id_info>
  <brief_title>ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence</brief_title>
  <official_title>Efficacy and Safety of VIVITROL® in Adults Completing Inpatient Treatment for Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to
      abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL.
      This Phase 3B trial was designed to evaluate the efficacy and safety of VIVITROL versus
      placebo. Injections were administered to patients in whom abstinence was enforced by a period
      of inpatient hospitalization of 7 to 21 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consisted of 2 parts, Part A and Part B. Part A was a double-blind,
      placebo-controlled assessment of safety and efficacy of VIVITROL versus placebo for 3 months.
      Part B was an open-label extension to assess longer-term safety, durability of effect, and
      health economics of VIVITROL when administered for up to 9 additional months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Percentage of Participants by Heavy Drinking Rate</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Cumulative percentage (%) of subjects reporting heavy drinking by category reflecting the various cut-offs for percentage of days that were heavy drinking days. A &quot;heavy drinking day&quot; was defined as 4 or more alcohol drinks in 1 day for women, and 5 or more alcohol drinks in 1 day for men. The Timeline Follow-Back (TLFB) method (Sobell &amp; Sobell: Humana Press, 1992) was utilized to collect subjects' daily drinking information (ie, the number of drinks consumed per day per subject which was retrospectively recalled and recorded in a diary).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Longer-term Safety of VIVITROL</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Number of subjects reporting at least 1 treatment-emergent adverse event (TEAE) while on study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>VIVITROL 380 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administered via intramuscular (IM) injection once every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for VIVITROL 380 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered via IM injection once every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIVITROL 380 mg</intervention_name>
    <description>Administered via IM injection once every 4 weeks.</description>
    <arm_group_label>VIVITROL 380 mg</arm_group_label>
    <other_name>naltrexone for extended-release injectable suspension</other_name>
    <other_name>Medisorb naltrexone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for VIVITROL 380 mg</intervention_name>
    <description>Administered via IM injection once every 4 weeks.</description>
    <arm_group_label>Placebo for VIVITROL 380 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Primary Inclusion Criteria:

          -  Current diagnosis of alcohol dependence, meeting at least 5 of DSM-IV criteria

          -  Expected to complete inpatient treatment for alcohol dependence within 24 hours of
             randomization

          -  Must have 7-21 days, inclusive, of inpatient treatment for alcohol dependence prior to
             first dose

          -  Negative urine toxicological screen for opioids on the day of randomization

          -  Women of childbearing potential must agree to use an approved method of contraception
             for the study duration

        Primary Exclusion Criteria:

          -  Pregnancy or lactation

          -  Evidence of hepatic failure including: ascites, bilirubin &gt;10% above upper limit of
             normal and/or esophageal variceal disease

          -  Current dependence (within the past year) to benzodiazepines, opioids or cocaine by
             DSM-IV criteria

          -  Use of any opioids and/or methadone within 14 days prior to the screening visit, or
             subjects likely to require opioid therapy during the study period

          -  Use of oral naltrexone, acamprosate, or disulfiram within 14 days prior to screening

          -  Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or
             PLG

          -  Parole, probation, or pending legal proceedings having the potential for incarceration
             during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard L. Silverman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Germany</country>
  </removed_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2007</study_first_submitted>
  <study_first_submitted_qc>July 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2007</study_first_posted>
  <results_first_submitted>March 23, 2011</results_first_submitted>
  <results_first_submitted_qc>March 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 13, 2011</results_first_posted>
  <last_update_submitted>September 20, 2011</last_update_submitted>
  <last_update_submitted_qc>September 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Addiction</keyword>
  <keyword>Alcoholism</keyword>
  <keyword>Inpatient detoxification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VIVITROL 380 mg</title>
          <description>Arm includes all subjects who received at least 1 injection of VIVITROL. After successfully completing screening subjects were administered VIVITROL 380 mg by intramuscular (IM) injection every 4 weeks for a total of 3 injections. Randomization was 1:1 (VIVITROL:placebo) and stratified by site.</description>
        </group>
        <group group_id="P2">
          <title>Placebo for VIVITROL 380 mg</title>
          <description>All subjects who received at least 1 injection of Placebo for VIVITROL. Arm includes all subjects who received at least 1 injection of placebo. After successfully completing screening subjects were administered placebo by intramuscular (IM) injection every 4 weeks for a total of 3 injections. Randomization was 1:1 (VIVITROL:placebo) and stratified by site.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A (Double-blind Period)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B (Open-label Period)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VIVITROL 380 mg</title>
          <description>Arm includes all subjects who received at least 1 injection of VIVITROL. After successfully completing screening subjects were administered VIVITROL 380 mg by intramuscular (IM) injection every 4 weeks for a total of 3 injections. Randomization was 1:1 (VIVITROL:placebo) and stratified by site.</description>
        </group>
        <group group_id="B2">
          <title>Placebo for VIVITROL 380 mg</title>
          <description>All subjects who received at least 1 injection of Placebo for VIVITROL. Arm includes all subjects who received at least 1 injection of placebo. After successfully completing screening subjects were administered placebo by intramuscular (IM) injection every 4 weeks for a total of 3 injections. Randomization was 1:1 (VIVITROL:placebo) and stratified by site.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="152"/>
            <count group_id="B2" value="148"/>
            <count group_id="B3" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="8.5"/>
                    <measurement group_id="B2" value="46.1" spread="8.3"/>
                    <measurement group_id="B3" value="45.8" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Percentage of Participants by Heavy Drinking Rate</title>
        <description>Cumulative percentage (%) of subjects reporting heavy drinking by category reflecting the various cut-offs for percentage of days that were heavy drinking days. A &quot;heavy drinking day&quot; was defined as 4 or more alcohol drinks in 1 day for women, and 5 or more alcohol drinks in 1 day for men. The Timeline Follow-Back (TLFB) method (Sobell &amp; Sobell: Humana Press, 1992) was utilized to collect subjects' daily drinking information (ie, the number of drinks consumed per day per subject which was retrospectively recalled and recorded in a diary).</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>The primary endpoint is based on percentage rate of heavy drinking days during the double-blind treatment period as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Vivitrol</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Percentage of Participants by Heavy Drinking Rate</title>
          <description>Cumulative percentage (%) of subjects reporting heavy drinking by category reflecting the various cut-offs for percentage of days that were heavy drinking days. A &quot;heavy drinking day&quot; was defined as 4 or more alcohol drinks in 1 day for women, and 5 or more alcohol drinks in 1 day for men. The Timeline Follow-Back (TLFB) method (Sobell &amp; Sobell: Humana Press, 1992) was utilized to collect subjects' daily drinking information (ie, the number of drinks consumed per day per subject which was retrospectively recalled and recorded in a diary).</description>
          <population>The primary endpoint is based on percentage rate of heavy drinking days during the double-blind treatment period as per protocol.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0% Heavy Drinking Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8"/>
                    <measurement group_id="O2" value="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 10% Heavy Drinking Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2"/>
                    <measurement group_id="O2" value="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 20% Heavy Drinking Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8"/>
                    <measurement group_id="O2" value="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 30% Heavy Drinking Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3"/>
                    <measurement group_id="O2" value="79.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 40% Heavy Drinking Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.9"/>
                    <measurement group_id="O2" value="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 50% Heavy Drinking Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6"/>
                    <measurement group_id="O2" value="85.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 60% Heavy Drinking Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.9"/>
                    <measurement group_id="O2" value="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 70% Heavy Drinking Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1"/>
                    <measurement group_id="O2" value="89.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 80% Heavy Drinking Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4"/>
                    <measurement group_id="O2" value="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 90% Heavy Drinking Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4"/>
                    <measurement group_id="O2" value="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 100% Heavy Drinking Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis that there is no difference between two treatment groups (i.e. Placebo and Vivitrol) was tested using a two-sided Van der Waerden test. Response profiles were tabulated as a cumulative percent of subjects at each decile of percent heavy drinking days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.336</p_value>
            <method>Van der Waerden test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Longer-term Safety of VIVITROL</title>
        <description>Number of subjects reporting at least 1 treatment-emergent adverse event (TEAE) while on study.</description>
        <time_frame>up to 1 year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE collection began after a subject signed the informed consent form and continued until 30 days after the last dose of study drug was administered.</time_frame>
      <desc>All volunteered, elicited, and observed AEs were recorded on the AE CRFs.</desc>
      <group_list>
        <group group_id="E1">
          <title>VIVITROL 380 mg (Double-blind Period)</title>
        </group>
        <group group_id="E2">
          <title>Placebo for VIVITROL 380 mg (Double-blind Period)</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Bereavement reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Emotional distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Psychosomatic disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Alcohol detoxification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No individual Investigator may publish results without written agreement from Alkermes. Should an Investigator wish to publish or present the data at a meeting, a copy of the manuscript or abstract must be provided to the Sponsor at least 30 days prior to the submission for review and approval. Any revisions will be negotiated in good faith by the Investigator and Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bernard L. Silverman, MD</name_or_title>
      <organization>Alkermes, Inc.</organization>
      <phone>1-781-609-6000</phone>
      <email>bernard.silverman@alkermes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

